Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience
ANNALS OF ONCOLOGY, vol.16, no.1, pp.146-151, 2005 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 16 Issue: 1
- Publication Date: 2005
- Doi Number: 10.1093/annonc/mdi017
- Journal Name: ANNALS OF ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.146-151
- Keywords: EBMT, extragonadal, high-dose chemotherapy, non-seminomatous germ cell tumor, second-line chemotherapy, SALVAGE CHEMOTHERAPY, PROGNOSTIC VARIABLES, CISPLATIN
- Ankara University Affiliated: Yes
Abstract
Background: Results of second-line chemotherapy in patients with extragonadal non-seminomatous germ cell tumor (NSGCT) appear inferior to results in testicular NSGCT. Patients with retroperitoneal NSGCT achieve a comparable long-term survival rate of 30%, but the salvage rates of patients with mediastinal primary are less than 10%. We conducted a retrospective analysis on patients with mediastinal and retroperitoneal NSGCT treated with second-line high-dose chemotherapy (HDCT) registered with the European Group for Blood and Marrow Transplantation (EBMT).